Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on BOD Australia.
RELATED STOCKHEAD STORIES
Health & Biotech
Weed Week: BOD advances Aqua Phase acquisition with stability testing
Health & Biotech
Weed Week: Oregon pardons cannabis convictions and bulk people light up on Turkey Day
Health & Biotech
ASX Health Stocks: Pot stock BOD’s Phase 1 results; Paradigm and Impedimed shake up exec teams
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
ASX Health Stocks: Immutep now patently Japanese; Patrys preps Phase 1 trial of brain cancer drug
Health & Biotech
Weed Week: Legal use of medicinal cannabis in Australia on the rise, Lambert Initiative says
Health & Biotech
ASX Health Stocks: Big announcements as Invex and Antisense jump over 20pc this morning
Health & Biotech
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Health & Biotech
ASX Health Stocks: Vectus jumps 13pc on promising Phase 1 study results
Health & Biotech
Weed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resort
Health & Biotech
ASX Health Stocks: Genetic Tech is now lab certified and begins rollout of its geneType Multi-Test
News
Weed Week: France temporarily overturns CBD ban and Canada gets a classy culinary cannabis facility
Health & Biotech
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
Health & Biotech
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug
Health & Biotech